Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 60% of ED Treatments Sold Online Are Counterfeits
December 21, 2009
- TMX-67 to Drive Teijin's Business: Mr Ohyagi
December 21, 2009
- Benefits of an Attitude of Gratitude
December 21, 2009
- Takara Bio Obtains Patent on Expansion Culture of Lymphocytes
December 21, 2009
- DPP-4/GLP-1 Drugs Need Further Assessment in Actual Medical Practice: Prof. Niki
December 21, 2009
- CMIC Acquires DS Propharma's Shizuoka Plant
December 21, 2009
- Taxotere to Become New Treatment Option for Prostate Cancer: Prof. Akaza
December 21, 2009
- Cut and Thrust About 2% Price Cut for Long-Listed Drugs at Chuikyo
December 21, 2009
- Symbicort Renovates Asthma Treatment in Japan: Prof. Adachi
December 21, 2009
- Punishment Proposed by Korosho for Firms That Fail to Develop Requested Drugs
December 21, 2009
- OAB Still Undertreated: Prof. Takahashi
December 21, 2009
- Proposed FY2010 NHI Drug Pricing System Reform (Draft)
December 21, 2009
- Use of Biologics Recommended at Early Stage for RA
December 21, 2009
- Korosho Aims at First Net Increase in Medical Fees in 10 Years
December 21, 2009
- JCR to Verify Acceptability of New ACR/EULAR RA Criteria in Japan
December 21, 2009
- Hospital Market Key to Success of Prasugrel: Mr Shoda
December 21, 2009
- Chuikyo Members Fail to Reach Consensus on Medical Fee Revision Rate
December 21, 2009
- Children with New-Type Flu Not Treated with Tamiflu May Show Abnormal Behavior
December 21, 2009
- Role of DPC Hospitals Needs to Be Reconsidered: Councillor Karasawa
December 21, 2009
- Nippon Shinyaku Submits NDA for Azacitidine for MDS
December 21, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…